Budd-Chiari syndrome in Sweden: Epidemiology, clinical characteristics and survival - An 18-year experience

Liver International

Volumn 29, Issue 2, 2009, Pages 253-259

  Rajani, Rupesh ^a,b   Melin, Tor ^c   Björnsson, Einar ^d   Broomé, Ulrika ^e   Sangfelt, Per ^f   Danielsson, Åke ^g   Gustavsson, Anders ^h   Grip, Olof ^c   Svensson, Hans ⁱ   Lööf, Lars ^j   Wallerstedt, Sven ^d   Almer, Sven H C ^b  

^a RYHOV COUNTY HOSPITAL   (Sweden)

^b LINKÖPING UNIVERSITY   (Sweden)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

^d SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^e KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^f UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^g UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^h ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

ⁱ VRINNEVI HOSPITAL   (Sweden)

^j Central County Hospital   (Sweden)

more..

Author keywords

Budd Chiari syndrome; Epidemiology; Hepatic vein thrombosis; Prognosis; Risk factors

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; COUMARIN DERIVATIVE; DIURETIC AGENT; ISOSORBIDE MONONITRATE; LOW MOLECULAR WEIGHT HEPARIN; ORAL CONTRACEPTIVE AGENT;

ABDOMINAL PAIN; ADOLESCENT; ADULT; AGED; ANTICOAGULATION; ARTICLE; ASCITES; BUDD CHIARI SYNDROME; CHILD; CLINICAL ARTICLE; CLINICAL FEATURE; FEMALE; FOLLOW UP; HEPATOMEGALY; HUMAN; INCIDENCE; LIVER TRANSPLANTATION; LOW DRUG DOSE; MALE; MYELOPROLIFERATIVE DISORDER; PORTAL VEIN THROMBOSIS; PREVALENCE; RETROSPECTIVE STUDY; RISK FACTOR; SURVIVAL RATE; SWEDEN; THROMBOPHILIA; TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT;

ADOLESCENT; ADULT; AGED; BLOOD CHEMICAL ANALYSIS; BUDD-CHIARI SYNDROME; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; MALE; MIDDLE AGED; PREVALENCE; RISK FACTORS; STATISTICS, NONPARAMETRIC; SURVIVAL ANALYSIS; SWEDEN;

EID: 58149520586     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2008.01838.x     Document Type: Article

References (22)

1. Janssen HL, Garcia-Pagan JC, Elias E, Mentha G, Hadengue A, Valla DC. Budd-Chiari syndrome: A review by an expert panel. J Hepatol 2003; 38: 364-71.
2. Hadengue A, Poliquin M, Vilgrain V, et al. The changing scene of hepatic vein thrombosis: Recognition of asymptomatic cases. Gastroenterology 1994; 106: 1042-7.
3. Menon KV, Shah V, Kamath PS. The Budd-Chiari syndrome. N Engl J Med 2004; 350: 578-85.
4. Denninger MH, Chait Y, Casadevall N, et al. Cause of portal or hepatic venous thrombosis in adults: The role of multiple concurrent factors. Hepatology 2000; 31: 587-91.
5. Murad SD, Valla DC, De Groen PC, et al. Determinants of survival and the effect of portosystemic shunting in patients with Budd-Chiari syndrome. Hepatology 2004; 39: 500-8.
6. Zeitoun G, Escolano S, Hadengue A, et al. Outcome of Budd-Chiari syndrome: A multivariate analysis of factors related to survival including surgical portosystemic shunting. Hepatology 1999; 30: 84-9.
7. Okuda H, Yamagata H, Obata H, et al. Epidemiological and clinical features of Budd-Chiari syndrome in Japan. J Hepatol 1995; 22: 1-9.
8. Valla D. Hepatic venous outflow tract obstruction etiopathogenesis: Asia versus the West. J Gastroenterol Hepatol 2004; 19: 204-11.
9. Almdal TP, Sorensen TI. Incidence of parenchymal liver diseases in Denmark, 1981 to 1985: Analysis of hospitalization registry data. The Danish Association for the Study of the Liver. Hepatology 1991; 13: 650-5.
10. Plessier A, Sibert A, Consigny Y, et al. Aiming at minimal invasiveness as a therapeutic strategy for Budd-Chiari syndrome. Hepatology 2006; 44: 1308-16.
11. Murad SD, Valla DC, De Groen PC, et al. Pathogenesis and treatment of Budd-Chiari syndrome combined with portal vein thrombosis. Am J Gastroenterol 2006; 101: 83-90.
12. Lunde AS, Lundeborg S, Lettenstrom GS, Thygesen L, Huebner J. The person-number systems of Sweden, Norway, Denmark, and Israel. Vital Health Stat 1980; 2: 1-59.
13. Socialstyrelsen - State department of National Health and Welfare. Epidemiologiskt Centrum, Patientregistret 1964-2005 Kvalitet och innehåll. Stockholm: Socialstyrelsen, 2006.
14. Valla D, Casadevall N, Lacombe C, et al. Primary myeloproliferative disorder and hepatic vein thrombosis. A prospective study of erythroid colony formation in vitro in 20 patients with Budd-Chiari syndrome. Ann Intern Med 1985; 103: 329-34.
15. Patel RK, Lea NC, Heneghan MA, et al. Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome. Gastroenterology 2006; 130: 2031-8.
16. Smalberg JH, Murad SD, Braakman E, Valk PJ, Janssen HL, Leebeek FW. Myeloproliferative disease in the pathogenesis and survival of Budd-Chiari syndrome. Haematologica 2006; 91: 1712-3.
17. Mahmoud AE, Elias E, Beauchamp N, Wilde JT. Prevalence of the factor V Leiden mutation in hepatic and portal vein thrombosis. Gut 1997; 40: 798-800.
18. Mentha G, Giostra E, Majno PE, et al. Liver transplantation for Budd-Chiari syndrome: A European study on 248 patients from 51 centres. J Hepatol 2006; 44: 520-8.
19. Janssen HL, Meinardi JR, Vleggaar FP, et al. Factor V Leiden mutation, prothrombin gene mutation, and deficiencies in coagulation inhibitors associated with Budd-Chiari syndrome and portal vein thrombosis: Results of a case-control study. Blood 2000; 96: 2364-8.
20. Valla D, Le MG, Poynard T, Zucman N, Rueff B, Benhamou JP. Risk of hepatic vein thrombosis in relation to recent use of oral contraceptives. A case-control study. Gastroenterology 1986; 90: 807-11.
21. Mahmoud AE, Helmy AS, Billingham L, Elias E. Poor prognosis and limited therapeutic options in patients with Budd-Chiari syndrome and portal venous system thrombosis. Eur J Gastroenterol Hepatol 1997; 9: 485-9.
22. Horton JD, San Miguel FL, Ortiz JA. Budd-Chiari syndrome: Illustrated review of current management. Liver Int 2008; 28: 455-66.